BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dauvilliers Y, Shapiro C, Mayer G, Lammers GJ, Emsellem H, Plazzi G, Chen D, Carter LP, Lee L, Black J, Thorpy MJ. Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial. CNS Drugs 2020;34:773-84. [PMID: 32588401 DOI: 10.1007/s40263-020-00744-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Cuomo MC, Sheehan AH, Jordan JK. Solriamfetol for the Management of Excessive Daytime Sleepiness. J Pharm Pract 2021;:8971900211009080. [PMID: 33882756 DOI: 10.1177/08971900211009080] [Reference Citation Analysis]
2 Franceschini C, Pizza F, Cavalli F, Plazzi G. A practical guide to the pharmacological and behavioral therapy of Narcolepsy. Neurotherapeutics 2021;18:6-19. [PMID: 33886090 DOI: 10.1007/s13311-021-01051-4] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
3 Abad VC. Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives. Nat Sci Sleep 2021;13:75-91. [PMID: 33531850 DOI: 10.2147/NSS.S245020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]